mRNA新冠疫苗接种后广泛反应性淋巴及脾脏FDG摄取
一例75岁女性转移性肺腺癌缓解期患者,监测PET/CT发现颈部、胸部、腹部及盆腔新发广泛FDG高摄取淋巴结及脾脏FDG高摄取,无局部复发证据;短期随访PET示FDG高摄取近完全消退,追问病史得知异常PET前6天接种第五剂新冠mRNA疫苗。
要点
- 新冠mRNA疫苗接种后可出现广泛对称性淋巴及脾脏FDG高摄取,属罕见现象。
- 该现象可在短期随访PET中近完全消退,无需改变管理策略。
- 单侧腋窝淋巴结肿大是新冠疫苗接种后公认表现,但广泛对称性淋巴及脾脏FDG高摄取显著更罕见。
核心结论
- 新冠mRNA疫苗接种后可出现广泛对称性淋巴及脾脏FDG高摄取,此为显著更罕见的现象,短期随访可近完全消退。
研究设计与样本
- 病例报告:一例75岁女性转移性肺腺癌缓解期患者,行监测PET/CT及短期随访PET。
主要发现
- 监测PET/CT示颈部、胸部、腹部及盆腔新发广泛FDG高摄取淋巴结,脾脏FDG摄取强烈,无局部复发证据。
- 短期随访PET示FDG高摄取淋巴及脾脏近完全消退,期间管理策略无变化。
- 追问病史发现患者在异常PET前6天接种第五剂新冠mRNA疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 75-year-old woman with history of metastatic lung adenocarcinoma in remission develops new widespread FDG-avid lymphadenopathy in the neck, chest, abdomen, and pelvis on surveillance PET/CT, as well as intense FDG uptake in the spleen, without evidence of local recurrence. Short-term follow-up PET demonstrates near-complete resolution of FDG-avid lymphatic and splenic FDG avidity without interval change in management. Further history reveals that the patient received her fifth dose of COVID mRNA vaccine 6 days before the abnormal PET. Although unilateral axillary adenopathy after COVID vaccination is well-recognized, this widespread symmetric lymphatic and splenic FDG avidity is a significantly rarer phenomenon.
引用
- Kavanaugh M, Shah HJ. Widespread Reactive Lymphatic and Splenic FDG Avidity After mRNA COVID Vaccination. Clin Nucl Med. 2024. PMID: 38465978. doi:10.1097/RLU.0000000000005150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。